Mapping the Microglial Transcriptome: A New Atlas of RNA Splicing in Neurodegeneration

Microglia and Their Role in Neurodegeneration

Microglia are the resident immune cells of the brain, acting as first responders to injury and disease. Over the past decade, genome-wide association studies (GWAS) have consistently linked microglial genes to the risk of neurodegenerative diseases. However, most studies have focused on gene expression rather than RNA splicing—a process that allows a single gene to produce multiple protein variants, or isoforms.

Splicing can be influenced by genetic variants, leading to the production of different isoforms that may be beneficial or harmful. This study presents a new isoform-centric genomic atlas for microglia, called isoMiGA, to better understand these processes at a detailed molecular level.

The Power of Long-Read RNA Sequencing

Traditional RNA sequencing methods rely on short-read sequencing, which captures only small fragments of RNA and makes it challenging to reconstruct full-length isoforms. To overcome this limitation, the researchers used long-read RNA sequencing from postmortem human brains, enabling them to capture full-length RNA molecules and identify previously unknown microglial isoforms.

Key findings include:

• 35,879 novel microglia isoforms, many of which were previously undetectable using standard RNA sequencing methods.

• Alternative splicing events that differ by brain region, showing that microglial function is not uniform across different areas of the brain.

• New insights into neurodegenerative disease risk genes, including novel splicing events in TREM2, CD33, and PLCG2—genes strongly associated with Alzheimer’s disease.

By combining long-read sequencing with short-read RNA sequencing data from 555 human microglia samples, the researchers created a powerful resource for understanding how genetic risk factors influence disease pathways.

Genetic Variants and Splicing in Alzheimer’s and Parkinson’s Disease

One of the most important findings of the study is that many genetic variants associated with neurodegenerative diseases regulate splicing rather than overall gene expression. This means that rather than simply increasing or decreasing gene activity, these variants may alter the type of protein that is produced, potentially affecting disease progression.

For example:

• TREM2 and CD33, two well-known Alzheimer’s risk genes, were found to have novel splicing events that could impact microglial activation and immune responses in the brain.

• PLCG2, another Alzheimer’s-linked gene, showed previously unknown fusion isoforms that could influence its function in microglia.

• New splicing variants in Parkinson’s-associated genes, such as SIPA1L2, suggest that RNA processing defects may play a larger role in Parkinson’s than previously thought.

A New Era for Microglial Genomics and Disease Research

This study highlights the importance of RNA splicing as a key mechanism linking genetic risk to neurodegenerative diseases. By identifying novel isoforms and disease-associated splicing events, the isoMiGA atlas provides a valuable resource for future research.

Potential applications include:

• More precise genetic risk assessment – By focusing on splicing effects rather than just gene expression, researchers can improve models for predicting neurodegenerative disease risk.

• Targeting splicing pathways for new treatments – Many neurodegenerative diseases currently lack effective therapies. Modulating splicing could provide new therapeutic strategies, particularly for genes like TREM2, CD33, and PLCG2.

• Understanding regional brain differences – Since microglial function varies across brain regions, this study provides new insights into why certain brain areas are more vulnerable to diseases like Alzheimer’s and Parkinson’s.

Dr. Panagiotis Roussos, a senior author of the study, highlighted its significance:

“By using long-read RNA sequencing, we can now see a level of detail in microglial transcriptomes that was previously hidden. This new resource will be instrumental in understanding the genetic architecture of neurodegeneration.”

Conclusion

This research represents a major advance in understanding the genetic regulation of microglia, the immune cells that play a central role in neurodegenerative diseases. By mapping how RNA splicing is influenced by genetic variants, the isoMiGA atlas provides critical insights into how microglial dysfunction contributes to Alzheimer’s, Parkinson’s, and other disorders.

With continued advancements in long-read sequencing and RNA therapeutics, the possibility of targeting splicing defects to slow or prevent neurodegeneration is now within reach. This study lays the groundwork for future discoveries that could transform our ability to treat these devastating diseases.